Gilead Begins to Fill the Hole in its Pipeline
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 59 (Table of Contents)
Published: 5 May-2005
DOI: 10.3833/pdr.v2005.i59.684 ISSN: 1756-7874
Section: General
Abstract
Gilead Sciences entered into licensing agreement with Japan Tobacco (JT) to develop and commercialize Japan Tobacco’s HIV integrase inhibitor (JTK-303) in all countries of the world, excluding Japan...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018